Natural immunity to breast and prostate cancers is predicted by a novel, saturated
ordered mutation model fitted to USA (SEER) incidence data, a prediction consistent with
the latest ideas in immunosurveillance. For example, the prevalence of natural immunity to
breast cancer in the white female risk population is predicted to be 76.5%; this immunity
may be genetic and, therefore, inherited. The modeling also predicts that 6.9% of White
Females are born with a mutation necessary to cause breast cancer (the hereditary
form) and, therefore, are at the highest risk of developing it. By contrast,
16.6% of White Females are born without any such mutation but are nonetheless susceptible
to developing breast cancer (the sporadic form). The modeling determines
the required number of ordered mutations for a cell to become cancerous as well as the
mean time between consecutive mutations for both the sporadic and hereditary forms of the
disease. The mean time between consecutive breast cancer mutations was found to vary
between 2.59 - 2.97 years, suggesting that such mutations are rare events and establishing
an upper bound on the lifetime of a breast cell. The prevalence of immunity to breast
cancer is predicted to be 79.7% in Blacks, 86.5% in Asians, and 85.8% in Indians.
Similarly, the prevalence of immunity to prostate cancer is predicted to be 67.4% for
Whites, 50.5% for Blacks, 77.7% for Asians, and 78.6% for Indians. It is of paramount
importance to delineate the mechanism underlying immunity to these cancers.